Abstract:e15113 Background: Ephrin type-A receptor 2 (EphA2) is a glycoprotein of the ephrin receptor subfamily. EphA2 is primarily involved in tissue patterning during embryonic development, and its expression levels are low or absent in normal adult tissues. However, EphA2 overexpression has been observed in multiple malignant tumors such as bladder, cervical, ovarian, colorectal, lung and esophageal cancers. In addition to being a tumor biomarker, EphA2 plays an active role in tumor survival, metastasis and neo-angiogenesis, which can lead to poor prognosis for cancer patients. The broad overexpression in solid tumors and relatively low expression in normal adult tissues make EphA2 attractive for targeted radiopharmaceutical therapy (RPT). Methods: RAYZ-6114 is comprised of a macrocyclic peptide binder to EphA2, a linker, and DOTA chelator which can be complexed with different radiometals. RAYZ-6283 shares the same peptide binder and chelator with RAYZ-6114 but differs in the linker. The binding affinity, selectivity and cross-species reactivity to EphA2 and other Ephrin proteins were determined by surface plasma resonance (SPR). Target-mediated internalization was measured using flow cytometry. In vivo biodistribution and anti-tumor efficacy studies were performed in tumor-bearing athymic nude mice. A coagulopathy study was performed in Sprague Dawley rats. For tumor type identification, EphA2 immunohistochemistry (IHC) was performed on tumor microarrays (TMA) representing diverse tumor types. Results: IHC analyses of TMAs confirmed the expression of EphA2 in a multitude of solid tumors, with the highest positivity rates in cervical, pancreatic, bladder, colorectal, esophageal, and non-small cell lung cancers. RAYZ-6114 showed high binding affinity to human EphA2 with a K D of 0.03 nM. High-affinity binding was conserved across mouse, cynomolgus monkey, and human EphA2. No binding to other Ephrin type-A or Ephrin type-B proteins was detected, nor to EphA2-knockout cells. The binder rapidly and efficiently internalized in EphA2-positive H1299 cells upon target engagement, with ~75% internalized by 1 hour. In PC3 xenograft mice, 177 Lu-RAYZ-6283 showed sustained tumor uptake (~25% ID/g) for up to 48 hours and tumor/kidney ratios of 2.7, 3.3, and 5.9 at 24h, 48h, and day 7, respectively. Low uptake was seen in other normal tissues. Both 177 Lu- and 225 Ac- labelled RAYZ-6114 significantly inhibited tumor growth. Particularly, durable tumor regression and survival benefit were achieved by a single dose of 225 Ac-RAYZ-6114 (3 uCi), out-performing 177 Lu-RAYZ-6114 dosed at 3 mCi. All treatments were well tolerated. Conclusions: RAYZ-6114 and RAYZ-6283 are first-in-class, highly potent and selective macrocyclic peptide binders. Preclinical pharmacodynamic, pharmacokinetic, biodistribution and efficacy data demonstrated their potential for treatment of patients with EphA2-positive tumors.

Discovery And Characterization Of A Novel Cyclic Peptide That Effectively Inhibits Ephrin Binding To The Epha4 Receptor And Displays Anti-Angiogenesis Activity

Design, Synthesis and Characterization of Novel Small Molecular Inhibitors of Ephrin-B2 Binding to EphB4.

Structure-activity relationship analysis of peptides targeting the EphA2 receptor.

Pegylation Potentiates The Effectiveness Of An Antagonistic Peptide That Targets The Ephb4 Receptor With Nanomolar Affinity

A Synthetic Bivalent Peptide Ligand of EphB4 with Potent Agonistic Activity

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

Abstract B201: Selective Peptides for Targeting EphA2 in Cancer Cells

Structure-activity relationship study of a small cyclic peptide H-c[Lys-Pro-Glu]-Arg-OH: a potent inhibitor of Vascular Endothelial Growth Factor interaction with Neuropilin-1

Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide

Targeting Yap/Taz-Tead Protein-Protein Interactions Using Fragment-Based And Computational Modeling Approaches

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Enhanced EphB2-Specific Peptide Inhibitors through Stabilization of Polyproline II Helical Structure

A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor.

A self-assembling peptide targeting VEGF receptors to inhibit angiogenesis

Novel peptide binder for EphA2-targeted radiopharmaceutical therapy for multiple solid tumors.

Inhibitory Effect of Taspine Derivative TAD1822-7 on Tumor Cell Growth and Angiogenesis Via Suppression of EphrinB2 and Related Signaling Pathways

Identification and Characterization of a Novel Peptide Ligand of Tie2 for Targeting Gene Therapy

Suppression of Tumor Growth and Metastasis by a VEGFR-1 Antagonizing Peptide Identified from a Phage Display Library.

Identification and Characterization of a Novel Peptide Ligand of Epidermal Growth Factor Receptor for Targeted Delivery of Therapeutics.

Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment